Elashwah, A., Badran, A., Elshenawy, M., Azzam, A., Naguib, R., Alshibani, A., Alrakaf, R., Eldali, A., Amin, T. (2022). Outcome and Safety of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) +/- Intraoperative Radiation Therapy (IORT) in the Management of Peritoneal Sarcomatosis: A Real-World Experience. Research in Oncology, 18(1), 19-28. doi: 10.21608/resoncol.2021.99181.1153
Ahmed Elashwah; Ahmed Badran; Mahmoud A. Elshenawy; Ayman Azzam; Rania Naguib; Aisha Alshibani; Reem Alrakaf; Abdelmoniem Eldali; Tarek Amin. "Outcome and Safety of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) +/- Intraoperative Radiation Therapy (IORT) in the Management of Peritoneal Sarcomatosis: A Real-World Experience". Research in Oncology, 18, 1, 2022, 19-28. doi: 10.21608/resoncol.2021.99181.1153
Elashwah, A., Badran, A., Elshenawy, M., Azzam, A., Naguib, R., Alshibani, A., Alrakaf, R., Eldali, A., Amin, T. (2022). 'Outcome and Safety of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) +/- Intraoperative Radiation Therapy (IORT) in the Management of Peritoneal Sarcomatosis: A Real-World Experience', Research in Oncology, 18(1), pp. 19-28. doi: 10.21608/resoncol.2021.99181.1153
Elashwah, A., Badran, A., Elshenawy, M., Azzam, A., Naguib, R., Alshibani, A., Alrakaf, R., Eldali, A., Amin, T. Outcome and Safety of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) +/- Intraoperative Radiation Therapy (IORT) in the Management of Peritoneal Sarcomatosis: A Real-World Experience. Research in Oncology, 2022; 18(1): 19-28. doi: 10.21608/resoncol.2021.99181.1153
Outcome and Safety of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) +/- Intraoperative Radiation Therapy (IORT) in the Management of Peritoneal Sarcomatosis: A Real-World Experience
1Radiation Oncology Department, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
2Kasr Al-Aini Center for Clinical Oncology and Nuclear Medicine (NEMROCK), Faculty of Medicine, Cairo University, Cairo, Egypt
3Medical Oncology Department, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
4Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
5Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt
6Surgical Oncology Department, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
7General Surgery Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
8Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
9Clinical Science Department, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
10Internal Medicine Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
11Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Abstract
Background: Peritoneal sarcomatosis (PS) is an aggressive disease; cytoreductive surgery (CRS) could be curative. Aim: Can the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) +/- intraoperative radiation therapy (IORT) overcome treatment failure with an overall survival benefit. Methods: Retrospective review of the medical records of patients with PS treated by CRS, HIPEC and IORT at a comprehensive cancer center in the period between 2011-2016. Results: Twenty-four patients were identified. Fifteen were men and their median age was 58 years. Liposarcoma was the most frequent diagnosis (50%). Cytoreduction completeness (CC) score 0/1 was achieved in 19 patients, with a median pathological peritoneal cancer index (pPCI) of 12. Intraoperative radiation therapy was given in 16 patients. Eight patients developed grade III-IV Clavien-Dindo post-operative complications and 1 patient died 5 days post operative. Adjuvant chemotherapy was received in 9 patients. After a median follow-up of 28.5 months, the median PFS was 20.7 months, while the estimated 2- and 4-year PFS were 37.1% and 19.1%, respectively. The median OS was 176.5 months and the estimated 2- and 4-year OS were 95.8% and 79.8%, respectively. In the univariate analysis, the PFS differed significantly according to the CC score only. The median PFS for patients with CC 0-1 was 23.8 vs. 8.8 months for those with CC 2-3 (p = 0.027). Conclusions: The addition of HIPEC and IORT to CRS in the management of PS is feasible and safe. Comparing our results to several studies, this multimodality approach seems to improve local and regional control rates. A larger cohort of patients is needed for further evaluation and to give a concrete conclusion.
View on SCiNiTO
Top